Compare IONQ Inc (IONQ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

IONQ trades at $43.92, up 3.27% today, with a bullish technical signal and strong revenue growth of 287% in Q2 2026. Despite significant net losses and negative margins, the company's backlog surged to $485 million, and it secured a $28 million defense contract extension. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism about its quantum computing leadership.

Outlook: High growth potential in quantum computing with raised 2026 revenue guidance, but profitability remains distant. Risks include heavy cash burn, intense competition, and stock volatility. The stock offers speculative upside for growth investors tolerant of high risk.

Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.

Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.